SANUWAVE Health, Inc. filings document a Nevada medical-device company focused on directed-energy systems for advanced wound care and regenerative medicine. Form 8-K reports record results of operations, preliminary financial information, investor presentation materials and material-event disclosures related to the company’s wound care business.
Regulatory filings also cover governance and capital-market disclosure subjects, including annual meeting proxy proposals, director elections, auditor ratification, stockholder advisory votes on executive compensation, officer appointments, compensatory arrangements and separation agreements. Additional filings document accounting matters such as non-reliance on previously issued financial statements connected to historical sales and use tax liabilities.
SANUWAVE Health, Inc. entered into an amendment to its credit agreement on October 28, 2026. The lenders waived any default or event of default that has arisen or may arise from the fixed charge coverage ratio for the twelve-month period ending September 30, 2026, being below the required level.
The amendment requires written lender consent for any Permitted Acquisition or use of Restricted Payments to repurchase the company’s outstanding equity, subject to exceptions. It lowers the permitted amounts for other secured indebtedness and subsidiary investments from $500,000 to $250,000 each. SANUWAVE agreed to pay a $5,000 amendment fee.
SANUWAVE Health, Inc. director James Tyler received 11,286 stock options to acquire common stock on September 30, 2026. The options were fully vested at grant, carry an exercise price of $4.71 per share, and expire on September 30, 2031. The reported option position after the grant was 11,286.
SANUWAVE Health, Inc. reported that Chief Executive Officer and director Morgan C. Frank acquired 11,286 stock options on September 30, 2026. The options were fully vested at grant, carry an exercise price of $4.71 per share, and expire September 30, 2031. The reported post-transaction position was 11,286 options.
SANUWAVE Health, Inc. reported that director Gregory Matthew Bazar received a grant of 11,286 stock options on September 30, 2026. The options were fully vested at grant, carry an exercise price of $4.71 per share, and expire September 30, 2031. They are options to buy common stock, rather than common shares acquired outright.
SANUWAVE Health, Inc. director Jeffrey Blizard received a grant of 11,286 stock options to buy common stock on September 30, 2026. The options were fully vested at the grant date, have an exercise price of $4.71 per share and expire on September 30, 2031. This is an option grant, not a reported purchase of common shares.
SANUWAVE Health, Inc. director Ian D. Miller received a grant of 12,697 stock options on September 30, 2026, covering options to buy 12,697 shares of common stock. The options were fully vested at grant, carry an exercise price of $4.71 per share and expire on September 30, 2031. Miller's reported direct option position after the grant was 12,697 options.
SANUWAVE Health, Inc. (SNWV) received a Nasdaq notice on September 23, 2026, stating that its Market Value of Listed Securities (MVLS) had remained below the $50,000,000 minimum for continued listing on The Nasdaq Global Market for 30 consecutive business days. The notice does not immediately affect trading; its common stock continues on The Nasdaq Global Market, subject to other listing requirements.
SANUWAVE has until March 22, 2027, under a 180-calendar-day compliance period to regain the minimum. Compliance is restored if MVLS closes at $50,000,000 or more for a minimum of 10 consecutive business days during the period. If the company does not regain compliance by the deadline, Nasdaq will notify it that its securities are subject to delisting.
SANUWAVE Health, Inc. has a significant shareholder reported on a Schedule 13G/A. Solas Capital Management, LLC, a Delaware-based registered investment adviser, and its portfolio manager Frederick Tucker Golden report beneficial ownership of 610,968 shares of common stock. This represents 7.1% of the 8,598,976 common shares outstanding as of May 8, 2026, as represented by the company. Solas and Golden report no sole voting or dispositive power, but shared voting and shared dispositive power over 610,968 shares, which are held by two private funds and another sub-advised fund for the benefit of their investors. The funds themselves expressly disclaim beneficial ownership of the reported securities pursuant to Rule 13d-4.
Sanuwave Health reported Q2 2026 results with softer revenue and earnings. Revenue was $9.7 million, down 3% from $10.1 million, and gross margin was 76.2% versus 78.1% a year earlier. Ultramist system sales declined to 82 units from 116, while Ultramist applicator revenue grew 13% to $7.3 million, accounting for roughly three-quarters of total revenue.
The business shifted from profit to loss: Q2 operating loss was $0.3 million versus $1.4 million income, and net loss was $0.7 million versus $0.6 million income in Q2 2025. Adjusted EBITDA fell to $1.2 million from $3.2 million. Management highlighted a challenging advanced wound care market, CMS reimbursement changes, and a growing secondary market for used Ultramist systems as pressures on new system sales. In light of Medicare reimbursement developments and a CMS proposed rule for 2027 code 97610, Sanuwave withdrew its 2026 guidance and does not plan to provide new guidance until after CMS issues its final rule, anticipated in the fourth quarter of 2026.
SANUWAVE Health, Inc. reported Q2 2026 revenue of $9.7 million, down 3% from Q2 2025, and a net loss of $0.7 million versus prior-year net income of $0.6 million. For the first six months of 2026, revenue was $19.4 million, essentially flat year over year, while the net loss narrowed to $2.1 million from $5.6 million.
Gross margin remained high at 76% in Q2 2026 but declined modestly due to lower UltraMIST system volumes and pricing and a mix shift toward consumables. Operating expenses increased across general and administrative, selling and marketing, and research and development, driving an operating loss of $0.3 million for the quarter and $1.4 million year-to-date. Below operating income, total other expense improved sharply, helped by a large reduction in interest expense after a 2025 debt refinancing.
Cash and cash equivalents were $9.4 million at June 30, 2026, with $18.7 million outstanding on a secured term loan and $0.7 million drawn on a revolving credit facility; operating activities generated $0.8 million of cash in the first half. The company has accrued $4.5 million for state and local sales taxes, interest, and penalties and is resolving these exposures through voluntary disclosure agreements. Disclosure controls and internal control over financial reporting remained ineffective due to previously identified material weaknesses in accounting resources, revenue recognition and sales tax processes, and information technology controls, with remediation efforts ongoing.